🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT02117856
Active, not recruiting Not applicable

Complete Lower Dentures on 1 or 2 Implants

NCT02117856 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2002-11
Last updated
2019-06-19

Condition(s) studied

Tooth-lossEdentulous MouthComplete DentureComplete Lower Denture

Investigational drug(s) / intervention(s)

1 implant placed surgically in the mandibular midline2 implants placed surgically in the mandibular canine sitesSoft reline (Coe Comfort) of the existing complete lower denture2.25mm ball patrix placed on 1 healed implant2.25mm ball patrices placed on 2 healed implantsReline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower dentureReline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture

1 implant placed surgically in the mandibular midline: Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.

2 implants placed surgically in the mandibular canine sites: Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.

Soft reline (Coe Comfort) of the existing complete lower denture: Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).

2.25mm ball patrix placed on 1 healed implant: A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.

2.25mm ball patrices placed on 2 healed implants: 2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.

Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.

Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants

Study summary

This study is a randomized clinical trial to compare patient satisfaction and prosthetic outcomes with lower dentures retained by one or two implants. The investigators long-term objective is to establish evidence of the cost-effectiveness of a single implant intervention for improving tolerance to complete dentures. The investigators MAIN AIM will be to investigate patient satisfaction between and within groups with mandibular dentures retained by one or two implants over five years, and SECONDARILY to investigate the survival of implants, and the frequency of events to maintain the dentures and prosthetic attachments as clinically serviceable. Furthermore, multivariate analysis can assess the prediction of patient satisfaction with implant dentures based on various possible factors including age, health, demography and socioeconomic status, number of implants, and maintenance needs. Patient satisfaction will be measured by means of Visual Analogue Scales (VAS) including a measure of overall satisfaction and various specific aspects of satisfaction such as appearance, stability and comfort of the dentures.

The CENTRAL HYPOTHESIS is that mandibular complete dentures retained by single implants are at least as satisfying to patients over a five years period as those retained by two implants for the same period.

The SECONDARY HYPOTHESES are that:

i) there is no difference over five years between groups in the survival of original implants, or in the number of events for maintenance of the dentures or implant attachments; and ii) using each treatment group as it's own control, there is no change in patient satisfaction with lower dentures retained by either one or two implants during the five year loading period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * functional in English or accompanied by a responsible adult who can provide translation services * able to consent to, and participate in, the treatment provided * available for the duration of the study * edentulous and with at least six month's experience with conventional complete dentures * currently wearing conventional complete dentures that are esthetically satisfactory to the patient and technically acceptable in the judgment of the study prosthodontist(s) * medically/psychologically suitable for implant surgery in the judgment of the study dentists Exclusion Criteria: * insufficient alveolar bone height for implant(s) (\< 10 mm) * history of head and neck radiation * systemic or neurological disease, including: American Society of Anesthesiologists (ASA) Class 3 with recently diagnosed severe systemic disease, e.g. recent (within 6 months) myocardial infarction or stroke; risks associated with bacteraemia, e.g. immune compromise, steroids, in-dwelling catheters, stents, prosthetic heart valves, etc.; Type 1 diabetes, pituitary and adrenal insufficiency, and untreated hypothyroidism; chronic granulomatous disease, e.g. tuberculosis and sarcoidosis; bone disease, e.g. histiocytosis X, Paget's disease, fibrous dysplasia; history of congenital or acquired uncontrolled bleeding, e.g. coumadin * previous oral implant treatment * need for additional pre-prosthetic surgery * need for new complete dentures * medically/psychologically unsuitable for surgery in the opinion of the study dentists

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Oral Health Sciences, University of British Columbia Vancouver British Columbia

More University of British Columbia trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02117856 on ClinicalTrials.gov ↗ ← All trials in Canada